Search for: "Lisa Larrimore Ouellette"
Results 101 - 120
of 130
Sorted by Relevance
|
Sort by Date
1 Feb 2022, 6:48 am
Durvasula, Lisa Larrimore Ouellette, and Heidi L. [read post]
22 Mar 2017, 4:42 am
” In a Wall Street Journal op-ed, Daniel Hamel and Lisa Larrimore Ouellette maintain that the case is essentially “about price discrimination, the practice of charging higher prices to customers who likely can pay more and offering discounts to those who cannot,” and they urge the justices to “consider what their decision might mean for consumers beyond the U.S. [read post]
25 Mar 2013, 11:23 am
More from Lyle Denniston and Lisa Larrimore Ouellette. [read post]
21 Jan 2015, 2:46 am
Commentary comes from Lisa Larrimore Ouellette at Written Description. [read post]
2 Oct 2020, 7:10 am
Sherkow, Lisa Larrimore Ouellette, and Nicholson PriceIn recent weeks, a number of articles have reported great concern around the politicization of the approval process for future COVID-19 vaccines. [read post]
4 Mar 2021, 10:50 am
Sherkow, Lisa Larrimore Ouellette, Nicholson Price, and Rachel SachsAre patents the cause of—or solution to—COVID-19 vaccine innovation problems? [read post]
30 Mar 2020, 8:40 am
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob SherkowOne of the dizzying stream of innovation and health law stories to emerge last week is Oracle’s partnership with the White House to study unproven pharmaceuticals for treating COVID-19. [read post]
18 Jun 2020, 1:23 pm
Sherkow, Lisa Larrimore Ouellette, Nicholson Price, and Rachel SachsIn the United States, one of the most important factors in receiving COVID-19 testing or treatment is access to insurance. [read post]
13 Aug 2020, 8:09 am
Sherkow, Lisa Larrimore Ouellette, and Nicholson PriceIn this blog post series, we have written about the importance of ensuring an adequate supply of diagnostic testing for COVID-19, and about the challenges the United States has faced so far on this front. [read post]
12 Jan 2021, 9:04 am
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob S. [read post]
Why is HHS blocking FDA from regulating some diagnostics, and how will this affect COVID-19 testing?
25 Aug 2020, 4:50 pm
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob S. [read post]
19 May 2020, 3:30 pm
Sherkow, Lisa Larrimore Ouellette, Nicholson Price, and Rachel SachsLast week, we focused on incentives for developing clinical evidence supporting the use of remdesivir for COVID-19 and analyzed the FDA’s grant of an emergency use authorization (EUA) for the drug. [read post]
27 Sep 2021, 7:26 am
Sherkow, Lisa Larrimore Ouellette, Nicholson Price, and Rachel SachsHistorically, the United States’ preparedness for a pandemic is like Charles Dudley Warner’s aphorism on the weather: everybody talks about it but no one ever does anything. [read post]
10 Jul 2020, 8:59 am
Sherkow, Lisa Larrimore Ouellette, and Nicholson PricePolicymakers are expectantly awaiting the development of a COVID-19 vaccine, which they view as critical to future management of the pandemic. [read post]
19 Aug 2020, 10:58 am
Sherkow, Lisa Larrimore Ouellette, Nicholson Price, and Rachel SachsModerna, Inc., a Cambridge, MA-based biotech company, is a leading contender in the race to develop a SARS-CoV-2 vaccine. [read post]
21 Jan 2022, 8:35 am
Sherkow, Lisa Larrimore Ouellette, and Nicholson PriceThe FDA has now authorized three vaccines and several treatments (including both monoclonal antibodies and small-molecule drugs) for the prevention and treatment of COVID-19. [read post]
8 Jun 2022, 5:23 am
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob S. [read post]
22 Jul 2020, 12:12 pm
Sherkow, Lisa Larrimore Ouellette, Nicholson Price, and Rachel SachsOver 120 years ago, a milk wagon horse named Jim was the United States’ most potent weapon against a raging diphtheria epidemic. [read post]
25 Mar 2021, 1:24 pm
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob S. [read post]
9 Mar 2018, 12:54 pm
To give one example, in their recent article, Bayh-Dole Without Borders, Lisa Larrimore Ouellette and Daniel Hemel observe that an under-appreciated feature of making federal funding for research work as an economic policy is ensuring that U.S. companies are able to protect the results of that federally-funded research abroad. [read post]
